Pharma Bio Services (PBSV) AI Stock Analysis

47 Followers

Pharma Bio Services

(Other OTC:PBSV)

Select Model

Rating:52Neutral

Price Target:$0.51▲(1.00% Upside)

Action:reiterated

Date:11/07/26

The overall score of 52 reflects a high-risk, early-stage turnaround situation. The primary strength is the company's fortress-like, debt-free balance sheet, which provides a substantial runway. However, this is overshadowed by the critical risk of significant cash burn from operations and a lack of profitability, which is confirmed by a negative P/E ratio. The weak technical trend further suggests that the market is skeptical about the company's near-term prospects. The company's future hinges entirely on its ability to stem cash losses and achieve profitable operations.

Positive Factors

Very low leverageNear-zero debt materially reduces financial risk and interest burden, giving the company greater flexibility to manage operating volatility. This balance-sheet resilience can provide time to address weak profitability without the immediate pressure of significant creditor obligations or refinancing needs.

Negative Factors

Recent operating lossesPersistent operating and net losses weaken the company’s earnings base and make future performance dependent on a meaningful improvement in margins. Negative profitability also limits internally generated capital, reduces returns on the equity base, and raises concern about the sustainability of current operations.

Pharma Bio Services (PBSV) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $11.45M
Dividend Yield: ―
Average Volume (3M): 6,255
Price to Earnings (P/E): -1.4
Beta (1Y): 0.59
Revenue Growth: 3.25%
EPS Growth: ―
Country: US
Employees: 55
Sector: Healthcare
Sector Strength: 51
Industry: Specialty Business Services

Pharma Bio Services Business Overview & Revenue Model

Company Description

Pharma-Bio Serv, Inc. functions as a specialized consulting firm, providing services focused on regulatory compliance and the transfer of technology. The company offers its compliance expertise to a diverse range of clients, including those in the ph...

How the Company Makes Money

null

Pharma Bio Services Financial Statement Overview

Summary

Financial performance is a mixed bag. The balance sheet is exceptionally strong with zero debt and a massive equity base (Score 85), providing a solid foundation. However, the income statement (Score 65) shows a transformative but unprofitable revenue surge, and the cash flow statement (Score 30) is deeply negative, indicating significant cash burn. The overall financial health is heavily reliant on the balance sheet to fund unprofitable operations.

Income Statement

65Positive

Balance Sheet

85Very Positive

Cash Flow

30Negative

Financial statement breakdown
Breakdown	TTM	Oct 2025	Oct 2024	Oct 2023	Oct 2022	Jan 2022
Income Statement
Total Revenue	9.48M	9.00M	9.51M	16.98M	19.40M	20.12M
Gross Profit	3.07M	2.91M	2.52M	5.07M	4.88M	5.36M
EBITDA	-24.26K	134.81K	-1.11M	1.31M	1.23M	-3.78M
Net Income	-13.95M	-100.46K	-777.62K	1.31M	1.01M	-2.09M
Balance Sheet
Total Assets	11.44B	13.65M	16.29M	19.90M	20.65M	23.92M
Cash, Cash Equivalents and Short-Term Investments	8.58M	10.85M	12.75M	14.98M	14.46M	17.47M
Total Debt	0	28.83K	194.03K	346.51K	487.36K	617.42K
Total Liabilities	994.74M	1.74M	2.58M	3.78M	4.09M	5.01M
Stockholders Equity	10.44B	11.91M	13.72M	16.13M	16.56M	18.91M
Cash Flow
Free Cash Flow	-304.53M	-221.53K	-726.44K	1.88M	573.19K	794.00K
Operating Cash Flow	-304.53M	-214.89K	-566.70K	1.89M	592.46K	804.84K
Investing Cash Flow	-2.21B	-1.47M	-1.36M	-4.22M	-19.27K	1.30M
Financing Cash Flow	-1.72B	-1.75M	-1.73M	-1.76M	-3.53M	-1.75M

Pharma Bio Services Technical Analysis

Technical Analysis SentimentPositive

Last Price0.50

Price Trends

50DMA0.47Positive

100DMA0.50Positive

200DMA0.51Negative

Market Momentum

MACD0.01Negative

RSI53.56Neutral

STOCH83.19Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PBSV, the sentiment is Positive. The current price of 0.50 is above the 20-day moving average (MA) of 0.47, above the 50-day MA of 0.47, and below the 200-day MA of 0.51, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 53.56 is Neutral, neither overbought nor oversold. The STOCH value of 83.19 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PBSV.

Pharma Bio Services Risk Analysis

Pharma Bio Services disclosed 25 risk factors in its most recent earnings report. Pharma Bio Services reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Pharma Bio Services Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

PBSV against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PBSV	52Neutral	$11.45M	-1.39	-0.27%	―	3.25%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ZCMD	43Neutral	$4.33M	-0.00	-53.52%	―	-49.58%	-31.56%
VSEE	41Neutral	$554.18K	-0.01	-400.87%	―	-9.31%	89.42%
HCTI	38Underperform	$3.89M	-0.00	-56.46%	―	116.40%	99.31%

* Healthcare Sector Average

Performance Comparison

PBSV and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
PBSV	Pharma Bio Serv Inc	0.50	-0.02	-4.40%
ZCMD	Zhongchao Inc	0.93	-984.13	-99.91%
HCTI	Healthcare Triangle, Inc.	3.74	-2504.26	-99.85%
VSEE	Vsee Health, Inc.	0.47	-58.87	-99.21%
ACON	Aclarion, Inc.	1.59	-4.57	-74.19%
BFRG	BullFrog AI Holdings, Inc.	0.55	-0.45	-44.70%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 07, 2026

Pharma Bio Services AI Stock Analysis